MTOR and gastrointestinal stromal tumor: PTEN biomarker may help to improve clinical management of resected GIST patients (ie, increase surveillance) and may be used as stratification factor in adjuvant clinical trials dedicated to patients with GIST to further investigate combined treatments with TKIs and mTOR inhibitors and contribute to improve clinical outcome in patients with early-stage GIST.